Signatures of Genetic Control in Digestive and Liver Disorders


Our technology describes unique genetic signatures in patients with digestive diseases and liver disorders. Using comprehensive analysis of 735 microRNAs and 19,000 mRNAs, we have identified a unique set of microRNAs and/or mRNAs which predict disease phenotypes in patients with digestive and liver disorders. The identification of such point-of- care genetic signatures is significant for both personalized biomarkers and novel targeted biotherapeutics. These microRNAs and mRNAs function either together or separately thus modulating protein expressions in one or more signaling pathways. A particular noteworthy signature of genetic control includes miR-150, which is known to modulate target proteins within the Akt signaling pathways implicated in inflammatory processes as well as processes affecting cancer cell proliferation and/or survival.



Potential Commercial Applications: Competitive Advantages:
  • Personalized biomarkers
  • Novel targeted biotherapeutic
 
  • Point-of-care signatures from minimally invasive samples.
  • Protocol streamlined for high-throughput analysis.
  • Quantitative molecular diagnostics.
  • Unique microRNAs and/or mRNAs reveal biological targets within synergistic cellular pathways.


Development Stage:
  • Pilot
  • Early-stage
  • Pre-clinical
  • In vitro data available


Inventors:

Wendy Henderson (NINR)  ➽ more inventions...

Ralph Peace (NINR)  ➽ more inventions...

Nicolaas Fourie (NINR)  ➽ more inventions...

Sarah Abey (NINR)  ➽ more inventions...


Intellectual Property:
US Pat: 9,683,263 issued 2017-06-20
US Application No. 61/825,154 filed on 2013-05-20
US Application No. 61/825,489 filed on 2013-05-20
PCT Application No. PCT/US2014/038638 filed on 2014-05-19

Licensing Contact:
Vincent Kolesnitchenko, Ph.D.
Email: vk5q@nih.gov
Phone: 301-594-4115

OTT Reference No: E-349-2013-0
Updated: Nov 18, 2015